English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Ascites is the most common of the three major complications of cirrhosis; the other complications are hepatic encephalopathy and variceal hemorrhage [1]. Approximately 50% of patients with “compensated” cirrhosis develop ascites during 10 years of observation. Ascites is the most common complication of cirrhosis that leads to hospital admission [2]. Development of fluid retention in the setting of cirrhosis is an important landmark in the natural history of chronic liver disease: approximately 15% of patients with ascites succumb in 1 year and 44% succumb in 5 years [3]. Many patients are referred for liver transplantation after development of ascites. Refractory ascites develops in approximately 5-10% of all cases of cirrhosisrelated ascites and carries a high mortality rate [4]. The available therapies for patients with refractory ascites are repeated large volume paracentesis, transjugular intra hepatic portosystemic shunts, peritoneovenous shunts, and liver transplantation [5,6]. The mechanism by which refractory ascites develops in cirrhosis

global journal of pharmacy and pharmaceutical sciences

"Etilefrine Could Improve Response to Standard Medical Therapy in Chronic Hepatitis C Egyptian Patients with Cirrhotic Refractory Ascites: A Randomized Pilot Study"